Carlsbad, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced a series of key leadership and governance changes aimed at strengthening its executive team, enhancing financial transparency, and supporting the Company’s next phase of strategic growth. Executive Appointments Effective October 2, 2025, Jerry (Jiawei) Wang was appointed as Co-Chief Executive Officer, and Koti Meka was appointed as Chief Financial Officer of Qualigen Therapeutics. Mr. W ...